Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.
Quon HC, Ong A, Cheung P, Chu W, Chung HT, Vesprini D, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Loblaw A. Quon HC, et al. Among authors: panjwani d. Radiother Oncol. 2018 May;127(2):206-212. doi: 10.1016/j.radonc.2018.02.029. Epub 2018 Mar 15. Radiother Oncol. 2018. PMID: 29551231 Clinical Trial.
Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials.
Roy S, Loblaw A, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Helou J, Zhang L, Mamedov A, Deabreu A, Quon HC. Roy S, et al. Among authors: panjwani d. Clin Oncol (R Coll Radiol). 2019 Sep;31(9):621-629. doi: 10.1016/j.clon.2019.05.001. Epub 2019 May 21. Clin Oncol (R Coll Radiol). 2019. PMID: 31126725
Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials.
Alayed Y, Quon H, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Helou J, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Commisso A, Commisso K, Loblaw A. Alayed Y, et al. Among authors: panjwani d. Radiother Oncol. 2019 Nov;140:105-109. doi: 10.1016/j.radonc.2019.06.018. Epub 2019 Jun 29. Radiother Oncol. 2019. PMID: 31265940
Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy.
Alayed Y, Davidson M, Quon H, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Liu SK, Panjwani D, Helou J, Musunuru HB, Pang G, Korol R, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Commisso A, Commisso K, D'Alimonte L, Ho L, Bhounr Z, Loblaw A. Alayed Y, et al. Among authors: panjwani d, d alimonte l. Radiother Oncol. 2020 Mar;144:135-140. doi: 10.1016/j.radonc.2019.11.017. Epub 2019 Dec 3. Radiother Oncol. 2020. PMID: 31809979
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT).
Alayed Y, Quon H, Ong A, Cheung P, Chu W, Chung H, Vesprini D, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Loblaw A. Alayed Y, et al. Among authors: panjwani d. Radiother Oncol. 2020 Aug;149:8-13. doi: 10.1016/j.radonc.2020.04.039. Epub 2020 Apr 27. Radiother Oncol. 2020. PMID: 32416376 Clinical Trial.
Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials.
Kennedy TAC, Ong WL, Quon H, Cheung P, Chu W, Chung H, Vesprini D, Panjwani D, Alayed Y, Pang G, Korol R, Zhang L, Mamedov A, Deabreu A, Loblaw A. Kennedy TAC, et al. Among authors: panjwani d. Int J Radiat Oncol Biol Phys. 2025 Feb 1;121(2):325-330. doi: 10.1016/j.ijrobp.2024.09.009. Epub 2024 Sep 16. Int J Radiat Oncol Biol Phys. 2025. PMID: 39293531
43 results